We advised Acutus Medical on the SEC-registered stock offering

Davis Polk advised Acutus Medical, Inc. on its SEC-registered public offering of 5,500,000 shares of common stock for an aggregate price to the public of $77 million. The shares are listed on the Nasdaq Global Select Market under the symbol “AFIB.”

Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associate Sherry Tan. The intellectual property and technology transactions team included partner David R. Bauer. The tax team included partner Michael Farber and associate Bree Gong. Partner Veronica M. Wissel and associate Kathleen Ginder provided executive compensation advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post